-
N/A
-
-
18+Age Range
-
33Locations
-
Recruiting
Recruiting
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Inclusion Criteria: - Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma - Patient must reside in the USA. - Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry: 1. Newly-diagnosed multiple myeloma transplant-eligible 2. Patients undergoing their first ASCT 3. Newly-diagnosed multiple myeloma transplant-ineligible 4. Relapsed and/or refractory. Exclusion Criteria: - Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English. - Patient is on hospice. - Patient is receiving or has received an investigational agent < 28 days prior to randomization or during this pilot study.
Experimental: Patient App + HCP Portal (Cohort 1)
Experimental: Patient App Alone (Cohort 2)